opigolix

GnRH antagonist

Also Known As:

(1Z,2R)-N'-((5-(3-(2,5-Difluorophenyl)-2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-3-oxopropanoyl)-2-fluorophenyl)sulfonyl)-2-hydroxypropanimidamide; ASP1707; propanimidamide, N'-((5-(3-(2,5-difluorophenyl)-2-(1,3-dihydro-2H-benzimidazol-2-ylidene)-1,3-dioxopropyl)-2-fluorophenyl)sulfonyl)-2-hydroxy-, (1Z,2R)-

Networked: 5 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Al-Hendy, Ayman: 1 article (10/2021)
2.	Binkley, Neil: 1 article (10/2021)
3.	Owens, Charlotte D: 1 article (10/2021)
4.	Puscheck, Elizabeth E: 1 article (10/2021)
5.	Schlaff, William D: 1 article (10/2021)
6.	Shebley, Mohamad: 1 article (10/2021)
7.	Simon, James A: 1 article (10/2021)
8.	Watts, Nelson B: 1 article (10/2021)
9.	Akazawa, Rio: 1 article (01/2021)
10.	Higashitani, Chieri: 1 article (01/2021)

Related Diseases

1.	Pelvic Pain 01/01/2019 - "A sample size of 504 (84 subjects per group) was calculated to provide ≥80% power to detect a dose-related treatment effect among placebo and ASP1707 doses in change from baseline in pelvic pain, assuming different dose-response curves after 12 weeks of treatment. " 01/01/2019 - "Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study." 01/01/2019 - "ASP1707 significantly reduced endometriosis-associated pelvic pain in a dose-related manner. " 01/01/2019 - "After 12 weeks of treatment with ASP1707, the mean (95% CI) changes in numeric rating score (NRS) for overall pelvic pain (OPP) were -1.56 (-1.91, -1.21), -1.63 (-1.99, -1.27), -1.93 (-2.27, -1.60), -2.29 (-2.64, -1.94), and -2.13 (-2.47, -1.79) for placebo, ASP1707 3 mg, ASP1707 5 mg, ASP1707 10 mg, and ASP1707 15 mg, respectively. " 01/01/2019 - "Of 912 women with endometriosis-associated pelvic pain screened, 540 were enrolled, and 532 received ≥1 dose of study drug (placebo, n = 88; ASP1707 3 mg, n = 86; ASP1707 5 mg, n = 91; ASP1707 10 mg, n = 90; ASP1707 15 mg, n = 88; leuprorelin, n = 89) for 24 weeks. "
2.	Endometriosis 01/01/2019 - "Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study." 01/01/2019 - "ASP1707 significantly reduced endometriosis-associated pelvic pain in a dose-related manner. " 01/01/2019 - "Of 912 women with endometriosis-associated pelvic pain screened, 540 were enrolled, and 532 received ≥1 dose of study drug (placebo, n = 88; ASP1707 3 mg, n = 86; ASP1707 5 mg, n = 91; ASP1707 10 mg, n = 90; ASP1707 15 mg, n = 88; leuprorelin, n = 89) for 24 weeks. " 01/01/2019 - "ASP1707 is a potential alternative treatment to leuprorelin for endometriosis-associated pelvic pain with lower impact on bone health. " 01/01/2019 - "Does the GnRH antagonist, ASP1707, reduce endometriosis-associated pelvic pain? "
3.	Rheumatoid Arthritis 01/01/2021 - "A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate."
4.	Dysmenorrhea (Menstrual Pain) 01/01/2019 - "Statistically significant dose-related treatment effects in reduction in NRS for OPP (P = 0.001), dysmenorrhea (P < 0.001), and NMPP (P = 0.029) were observed after 12 weeks among ASP1707 doses and were maintained through 24 weeks. " 10/01/2023 - "Elagolix 400 mg and ASP1707 15 mg were most efficient in reducing pelvic pain, dysmenorrhea and dyspareunia. "
5.	Menorrhagia 10/01/2021 - "Development of newer medical therapies, principally GnRH antagonists (e.g., ASP1707, elagolix, linzagolix, relugolix), for treatment of endometriosis-associated pelvic pain and heavy menstrual bleeding due to uterine fibroids has renewed interest in the short- and long-term impacts of changes in BMD experienced by premenopausal women. "

Related Drugs and Biologics

1.	Gonadotropin-Releasing Hormone (GnRH)
2.	Leuprolide (Lupron)
3.	Methotrexate (Mexate)
4.	elagolix
5.	relugolix
6.	linzagolix
7.	Mifepristone (RU 486)
8.	Cabergoline
9.	4-(2-oxapentadeca-4-yne)phenylpropanoic acid

Related Therapies and Procedures

1.	Therapeutics